Juan Arroyo Ornelas, M.D., Ph.D.

Assistant Professor of Medicine (Nephrology and Hypertension), Cell & Developmental Biology, and Molecular Physiology & Biophysics

Juan Arroyo Ornelas, M.D., Ph.D.

Assistant Professor of Medicine (Nephrology and Hypertension), Cell & Developmental Biology, and Molecular Physiology & Biophysics

juan.p.arroyo@vumc.org

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

Read more about Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet.

RESEARCH THEMES

The Cancer Cell Biology program is organized into four groups with common research interests:

Cell Cycle Control

Identifying how changes in key cell cycle proteins help tumor cells escape the typical response of cell death and lead to uncontrollable growth

Chemical Biology

Finding and developing compounds that inhibit key drivers of cancer formation

Signaling Networks

Combining ‘big data’ experimental approaches to understand the changes in signaling networks that drive cancer formation

Stem Cell Biology

Determining how cancer-initiating stem cells continuously renew and seed distant sites to promote metastasis, and understanding the role of these cells in resistance to chemotherapies

Cancer Cell Biology Research Program

The pathways that send chemical signals from the cell surface to the nucleus are major targets of genotype-driven therapies for cancer. The Cancer Cell Biology Research Program aims to better understand how changes in tumor cells alter these signaling networks, and to identify—or create—molecules that target these pathways as potential new therapies for cancer.

Program Leader

Jin Chen, MD, PhD.

Program Leader

Katrin Karbstein, Ph.D.

All Program Members

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Read more about A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.